Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Aussie lab test company Healthscope sees NZ pathology growth

Aussie lab test company Healthscope sees growth in NZ pathology business

By Pam Graham

July 1 (BusinessDesk) - Australia’s Healthscope is confident of winning more contracts for pathology services in New Zealand where it already services 65 percent of the population.

The size of the company’s business in New Zealand and its ambitions for more growth have been detailed in a prospectus for a share offer in Australia.

“Operationally, Healthscope is focused on extracting further economies of scale, including cost synergies, through the operational integration of its expanding laboratory network,” the prospectus says.

The company trades under the Labtests, SCL and Northland brands, and as at May 19, 2014, it operated 13 labs across New Zealand. It will seek additional DHB contracts as they come up and says it is well positioned to win them.

The company already has 10 contracts with district health boards in New Zealand. It provided lab testing services for more than five million patient episodes in the 12 months ended Dec. 31, 2013. Its Labtests Auckland does 33 percent of total annual volume of DHB pathology work in New Zealand, according to the prospectus.

The document says Healthscope is a market leader in New Zealand and management estimates it services 65 percent of the population. The Auckland contract started in September 2009 and runs until September 2020.

In December 2011 the company was awarded a new pathology contract in the Canterbury region. It acquired Medlab South in 2012. It also has a veterinary pathology business called Gribbles Veterinary.

The company prospectus does not disclose earnings for New Zealand, lumping them in an international division which also operates in Malaysia, Singapore and Vietnam.

Earnings before interest, tax, depreciation and amortisation for the international pathology division rose to $A44.5 million in the 2013 financial year from $A38.7 million in the 2013 year.

(BusinessDesk)

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

By May 2018: Wider, Earlier Microbead Ban

The sale and manufacture of wash-off products containing plastic microbeads will be banned in New Zealand earlier than previously expected, Associate Environment Minister Scott Simpson announced today. More>>

ALSO:

Snail-ier Mail: NZ Post To Ditch FastPost

New Zealand Post customers will see a change to how they can send priority mail from 1 January 2018. The FastPost service will no longer be available from this date. More>>

ALSO:

Property Institute: English Backs Of Debt To Income Plan

Property Institute of New Zealand Chief Executive Ashley Church is applauding today’s decision, by Prime Minister Bill English, to take Debt-to-income ratios off the table as a tool available to the Reserve Bank. More>>

ALSO:

Divesting: NZ Super Fund Shifts Passive Equities To Low-Carbon

The NZ$35 billion NZ Super Fund’s NZ$14 billion global passive equity portfolio, 40% of the overall Fund, is now low-carbon, the Guardians of New Zealand Superannuation announced today. More>>

ALSO:

Split Decision - Appeal Planned: EPA Allows Taranaki Bight Seabed Mine

The Decision-making Committee, appointed by the Board of the Environmental Protection Authority to decide a marine consent application by Trans-Tasman Resources Ltd, has granted consent, subject to conditions, for the company to mine iron sands off the South Taranaki Bight. More>>

ALSO: